The mucosal injury of small intestine in regular users of COX-2 selective inhibitor (Celecoxib) investigated by capsule endoscopy

The mucosal injury of small intestine in regular users of COX-2 selective inhibitor (Celecoxib) investigated by capsule endoscopy - Capsule endoscopic findings in regular users of COX-2 selective inhibitor

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000007403

Enrollment

Registered

2012-02-29

Start date

2011-11-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Mucosal injury of small intestine due to COX-2 selective inhibitor

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Regular users of the COX-2 selective inhibitor who have already used it more than 4 weeks

Exclusion criteria

Exclusion criteria: 1) Patients taking misoprostol 2) Patients taking other NSAIDs, steroid, anti-platelet agents except aspirin, anti-coagulants, or anti-cancer drugs 3) Patients with contraindication to capsule endoscopy 4) Patients with active bleeding lesions 5) Severely ill patients

Design outcomes

Primary

Measure	Time frame
The prevalence of small intestinal lesions evaluated by capsule endoscopy	—

Secondary

Measure	Time frame
Grade and number of the small intestinal lesions, The relationship between small intestinal lesions and patients' factors	—

Countries

Japan

Contacts

Public ContactYutaka Yamaji

The University of Tokyo Hospital Department of Gastroenterology

yamaji-tky@umin.ac.jp03-3815-5411

Outcome results